Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum.
van der Sluis TC, Beyrend G, van der Gracht ETI, Abdelaal T, Jochems SP, Belderbos RA, Wesselink TH, van Duikeren S, van Haften FJ, Redeker A, Ouboter LF, Beyranvand Nejad E, Camps M, Franken KLMC, Linssen MM, Hohenstein P, de Miranda NFCC, Mei H, Bins AD, Haanen JBAG, Aerts JG, Ossendorp F, Arens R. van der Sluis TC, et al. Among authors: bins ad. Cell Rep Med. 2023 Mar 21;4(3):100939. doi: 10.1016/j.xcrm.2023.100939. Epub 2023 Feb 15. Cell Rep Med. 2023. PMID: 36796366 Free PMC article.
Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT.
Bouman-Wammes EW, van Dodewaard-De Jong JM, Dahele M, Cysouw MCF, Hoekstra OS, van Moorselaar RJA, Piet MAH, Verberne HJ, Bins AD, Verheul HMW, Slotman BJ, Oprea-Lager DE, Van den Eertwegh AJM. Bouman-Wammes EW, et al. Among authors: bins ad. Clin Genitourin Cancer. 2017 Oct;15(5):e773-e782. doi: 10.1016/j.clgc.2017.03.009. Epub 2017 Mar 29. Clin Genitourin Cancer. 2017. PMID: 28462855
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B; ARASENS Trial Investigators. Smith MR, et al. N Engl J Med. 2022 Mar 24;386(12):1132-1142. doi: 10.1056/NEJMoa2119115. Epub 2022 Feb 17. N Engl J Med. 2022. PMID: 35179323 Free PMC article. Clinical Trial.
Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature.
Opdam M, van der Noort V, Kleijn M, Glas A, Mandjes I, Kleiterp S, Hilbers FS, Kruger DT, Bins AD, de Jong PC, Schiphorst PPJBM, van Dalen T, Flameling B, Rietbroek RC, Beeker A, van den Heiligenberg SM, Bakker SD, Wymenga ANM, Oving IM, Bijlsma RM, van Diest PJ, Vermorken JB, van Tinteren H, Linn SC. Opdam M, et al. Among authors: bins ad. Breast Cancer Res Treat. 2022 Jul;194(2):265-278. doi: 10.1007/s10549-022-06618-z. Epub 2022 May 19. Breast Cancer Res Treat. 2022. PMID: 35587322 Free PMC article. Clinical Trial.
Design and use of conditional MHC class I ligands.
Toebes M, Coccoris M, Bins A, Rodenko B, Gomez R, Nieuwkoop NJ, van de Kasteele W, Rimmelzwaan GF, Haanen JB, Ovaa H, Schumacher TN. Toebes M, et al. Nat Med. 2006 Feb;12(2):246-51. doi: 10.1038/nm1360. Epub 2006 Feb 5. Nat Med. 2006. PMID: 16462803
45 results